Sarepta Therapeutics shares surge 20% on early data for rare disease drugs, signaling a fragile comeback after gene therapy crisis

Sarepta Therapeutics is attempting a high-stakes turnaround, with its stock soaring over 20% on the back of promising early clinical data for two new muscular dystrophy drugs. This surge represents a critical vote of confidence from investors, but it comes against the backdrop of a company still reeling from a catastrophic 2025. That year, multiple patient deaths linked to its top-selling gene therapy forced a corporate crisis, leading to the layoff of more than one-third of its workforce and derailing its primary business.

The preliminary safety and efficacy data for the drugs, SRP-1001 and SRP-1003, offer a glimmer of hope for Sarepta's future, which is now entirely staked on this pipeline of unproven treatments for related rare, muscle-wasting diseases. The company presented the early-stage trial results as a positive, though incremental, step. However, the real tests are still to come; Sarepta stated that more substantive data updates are expected later this year, with pivotal studies not slated to begin until 2027.

The dramatic share price movement underscores the intense pressure on Sarepta to successfully rebuild. The market's reaction highlights both the desperate need for new therapies in the rare disease space and the precarious nature of biotech comebacks following severe safety scandals. The company's long-term viability now hinges on converting this early promise into robust late-stage clinical success, a process fraught with risk and years away from providing definitive answers.